|Trade names||Impavido, Miltex, others|
|Defined daily dose||not established|
|Metabolism||Slow hepatic (non-CYP-dependent)|
|Elimination half-life||6 to 8 days and 31 days|
|Chemical and physical data|
|Molar mass||407.576 g·mol−1|
|3D model (JSmol)|
|Melting point||232 to 234 °C (450 to 453 °F)|
|(what is this?)|
Miltefosine, sold under the trade name Impavido among others, is a medication mainly used to treat leishmaniasis and free-living amoeba infections such as Naegleria fowleri and Balamuthia mandrillaris. This includes the three forms of leishmaniasis: cutaneous, visceral and mucosal. It may be used with liposomal amphotericin B or paromomycin. It is taken by mouth.
Common side effects include vomiting, abdominal pain, fever, headaches, and decreased kidney function. More severe side effects may include Stevens–Johnson syndrome or low blood platelets. Use during pregnancy appears to cause harm to the baby and use during breastfeeding is not recommended. How it works is not entirely clear.
Miltefosine was first made in the early 1980s and studied as a treatment for cancer. A few years later it was found to be useful for leishmaniasis and was approved for this use in 2002 in India. It is on the World Health Organization's List of Essential Medicines. In the developing world a course of treatment costs US$65 to $150. In the developed world treatment may be 10 to 50 times greater.
Miltefosine is primarily used for the treatment of visceral and New World cutaneous leishmaniasis, and is undergoing clinical trials for this use in several countries. This drug is now listed as a core medication for the treatment of leishmaniasis under the WHO Model List of Essential Medicines. Several medical agents have some efficacy against visceral or cutaneous leishmaniasis, however, a 2005 survey concluded that miltefosine is the only effective oral treatment for both forms of leishmaniasis.
Miltefosine has been used successfully in some cases of the very rare, but highly lethal, brain infection by the amoeba, Naegleria fowleri, acquired through water entering the nose during a plunge in contaminated water. It has orphan drug status in the United States for acanthamoeba keratitis and primary amebic meningoencephalitis (PAM).
Pregnancy and breastfeeding
Miltefosine is listed as pregnancy category D by the FDA. This means there is evidence-based adverse reaction data from investigational or marketing experience or studies in humans of harm to the human fetus. Despite this evidence, the potential benefits of miltefosine may warrant use of the drug in pregnant women despite potential risks. A pregnancy test should be done prior to starting treatment. Effective birth control should be used while on miltefosine and 5 months after discontinuation of treatment. Its use during breast feeding is most likely unsafe.
Miltefosine is contraindicated in individuals who have a hypersensitivity to this medication, pregnant women, and people who have the Sjögren-Larsson syndrome. It is embryotoxic and fetotoxic in rats and rabbits, and teratogenic in rats but not in rabbits. It is therefore contraindicated for use during pregnancy, and contraception is required beyond the end of treatment in women of child-bearing age.
Mechanism of action
Miltefosine primarily acts on Leishmania by affecting the species's promastigote and amastigote stages. Miltefosine exerts its activity by interacting with lipids, inhibiting cytochrome c oxidase and causing apoptosis-like cell death. This may affect membrane integrity and mitochondrial function of the parasite.
While initially studied as a cancer medication, due to side effects it was never used for this purpose.
Phospholipid group alkylphosphocholine were known since the early 1980s, particularly in terms of their binding affinity with cobra venom. In 1987 the phospholipids were found to be potent toxins on leukemic cell culture. Initial in vivo investigation on the antineoplastic activity showed positive result, but then only at high dosage and at high toxicity. At the same time in Germany, Hansjörg Eibl, at the Max Planck Institute for Biophysical Chemistry, and Clemens Unger, at the University of Göttingen, demonstrated that the antineoplastic activity of the phospholipid analogue miltefosine (at the time known as hexadecylphosphocholine) was indeed tumour-specific. It was highly effective against methylnitrosourea-induced mammary carcinoma, but less so on transplantable mammary carcinomas and autochthonous benzo(a)pyrene-induced sarcomas, and relatively inactive on Walker 256 carcinosarcoma and autochthonous acetoxymethylmethylnitrosamine-induced colonic tumors of rats. It was subsequently found that miltefosine was structurally unique among lipids having anticancer property in that it lacks the glycerol group, is highly selective on cell types and acts through different mechanism.
In the same year as the discovery of the anticancer property, miltefosine was reported by S. L. Croft and his team at the London School of Hygiene and Tropical Medicine as having antileishmanial effect as well. The compound was effective against Leishmania donovani amastigotes in cultured mouse peritoneal macrophages at a dose of 12.8 mg/kg/day in a five-day course. However, priority was given to the development of the compound for cutaneous metastases of breast cancer. In 1992 a new research was reported in which the compound was highly effective in mouse against different life cycle stages of different Leishmania species, and in fact, more potent than the conventional sodium stibogluconate therapy by a factor of more than 600. Results of the first clinical trial in humans were reported from Indian patients with chronic leishmaniasis with high degree of success and safety. This promising development promulgated a unique public–private partnership collaboration between ASTA Medica (later Zentaris GmbH), the World Health Organization (WHO) Special Programme for Research and Training in Tropical Diseases, and the Government of India. Eventually, several successful Phase II and III trials led to the approval of miltefosine in 2002 as the first and only oral drug for leishmaniasis.
Naegleria fowleri and Acanthamoeba
In 2013, the US Centers for Disease Control and Prevention recommended miltefosine for the treatment of free-living amoeba infections such as granulomatous amoebic encephalitis and primary amoebic meningoencephalitis, two fatal protozoal diseases. Historically, only four survivors have been recorded out of 138 confirmed infections in North America. One American survived the infection in 1978 and one individual from Mexico in 2003. In 2013, two children survived and recovered from primary amoebic meningoencephalitis after treatment with miltefosine. In 2016 after treatment that included miltefosine, another child became the fourth person in the United States to survive Naegleria fowleri infection.
Society and culture
Miltefosine is commercially available in the United States through Profounda. Previously one could only get it from the CDC for emergency use under an expanded access IND protocol for treatment of free-living amoeba (FLA) infections: primary amoebic meningoencephalitis caused by Naegleria fowleri and granulomatous amoebic encephalitis caused by Balamuthia mandrillaris and Acanthamoeba species. Miltefosine is also produced by Profounda, a private pharmaceutical company.
Antiprotozoal and antifungal activities
Miltefosine is being investigated by researchers interested in finding treatments for infections which have become resistant to existing drugs. Animal and in vitro studies suggest it may have broad anti-protozoal and anti-fungal properties:
- Animal studies suggest miltefosine may also be effective against Trypanosoma cruzi, the parasite responsible for Chagas' disease.
- Several studies have found the drug to be effective against types of fungus: Cryptococcus neoformans, Candida, Aspergillus and Fusarium.
- A 2006 in vitro study found that miltefosine is effective against metronidazole-resistant variants of Trichomonas vaginalis, a sexually transmitted protozoal disease.
- Cetrimonium bromide, a compound related to miltefosine, was demonstrated in 2007 to exhibit potent in vitro activity against Plasmodium falciparum.
- An in vitro test in 2006 showed that miltefosine is effective against the deadly protozoan pathogens, Naegleria fowleri, Balamuthia mandrillaris, and Acanthamoeba. However, later studies showed that it is not as potent as other drugs, such as chlorpromazine and diminazene aceturate (Berenil).
- In 2013, there were reports of failure of miltefosine in the treatment of leishmaniasis. Although drug resistance was suspected, studies in 2014 reported that miltefosine is not so effective in children, most probably related to a lack of drug exposure in children. Moverover, males appeared to have a higher probability of relapse as well.
- A 2012 in vitro study found that miltefosine had promising activity against Candida albicans biofilms.
Miltefosine targets HIV infected macrophages, which play a role in vivo as long-lived HIV-1 reservoirs. The HIV protein Tat activates pro-survival PI3K/Akt pathway in primary human macrophages. Miltefosine acts by inhibiting the PI3K/Akt pathway, thus removing the infected macrophages from circulation, without affecting healthy cells. It significantly reduces replication of HIV-1 in cocultures of human dendritic cells (DCs) and CD4+ T cells, which is due to a rapid secretion of soluble factors and is associated with induction of type-I interferon (IFN) in the human cells.
- American Society of Health-System Pharmacists (26 February 2016). "Miltefosine Monograph for Professionals". www.drugs.com. Archived from the original on 17 November 2016. Retrieved 16 November 2016.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 21 September 2020.
- Dorlo, T. P. C.; Balasegaram, M.; Beijnen, J. H.; de Vries, P. J. (2012). "Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis". Journal of Antimicrobial Chemotherapy. 67 (11): 2576–2597. doi:10.1093/jac/dks275. PMID 22833634.
- "FDA approves Impavido to treat tropical disease leishmaniasis". U.S. Food and Drug Administration (FDA) (Press release). 19 March 2014. Archived from the original on 3 September 2014. Retrieved 30 August 2014.
- World Health Organization (March 2010). Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. World Health Organization. pp. 59, 88, 186. hdl:10665/44412. ISBN 9789241209496.
- Greenwood, David (2008). Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. OUP Oxford. p. 310. ISBN 9780199534845. Archived from the original on 2017-09-10.
- Kumar, Awanish (2013). Leishmania and Leishmaniasis. Springer Science & Business Media. p. 39. ISBN 9781461488699. Archived from the original on 2017-09-10.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- Cristina, Márcia; Pedrosa, Robert (September 2005). "Hospital de Doenças Tropicais testa droga contra calazar". Sapiência (in Portuguese). Fundação de Amparo à Pesquisa do Estado do Piauí. Archived from the original on 2006-08-22. Retrieved 2006-09-01.CS1 maint: unrecognized language (link)
- Soto J, Berman J (2006). "Treatment of New World cutaneous leishmaniasis with miltefosine". Trans R Soc Trop Med Hyg. 100: S34–40. doi:10.1016/j.trstmh.2006.02.022. PMID 16930649.
- WHO (2015). "19th WHO Model List of Essential Medicines" (PDF). Archived (PDF) from the original on 13 May 2015. Retrieved 8 November 2016.
- Berman, J. (2005). "Clinical status of agents being developed for leishmaniasis". Expert Opinion on Investigational Drugs. 14 (11): 1337–1346. doi:10.1517/135437184.108.40.2067. PMID 16255674.
- Linam, W. Matthew; Ahmed, Mubbasheer; Cope, Jennifer R.; Chu, Craig; Visvesvara, Govinda S.; Silva, Alexandre J. da; Qvarnstrom, Yvonne; Green, Jerril (2015-03-01). "Successful Treatment of an Adolescent With Naegleria fowleri Primary Amebic Meningoencephalitis". Pediatrics. 135 (3): e744–e748. doi:10.1542/peds.2014-2292. ISSN 0031-4005. PMC 4634363. PMID 25667249. Archived from the original on 2016-04-09.
- Inc., Profounda. "Profounda Inc. receives FDA orphan-drug designation for the Treatment of Primary Amebic Meningoencephalitis (PAM) with Miltefosine". www.prnewswire.com. Archived from the original on 2016-12-22. Retrieved 2017-05-25.
- Inc., Profounda. "FDA Orphan Drug Designation Granted to Profounda Inc. for the treatment of Acanthamoeba Keratitis with miltefosine". www.prnewswire.com. Archived from the original on 2016-12-21. Retrieved 2017-05-25.
- "New FDA Pregnancy Categories Explained - Drugs.com". www.drugs.com. Archived from the original on 2016-11-16. Retrieved 2016-11-16.
- "Impavido- miltefosine capsule". DailyMed. Profounda, Inc. 5 June 2019. Retrieved 26 December 2019.
- Sindermann, H.; Engel, J. (2006). "Development of miltefosine as an oral treatment for leishmaniasis". Transactions of the Royal Society of Tropical Medicine and Hygiene. 100 (Suppl 1): S17–S20. doi:10.1016/j.trstmh.2006.02.010. PMID 16730362.
- "Miltefosine Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 2016-11-17. Retrieved 2016-11-16.
- "Drugs.com - Miltefosine Side Effects". Archived from the original on 2016-11-17.
- S.D. Seth (2008). "Drug therapy of leishmaniasis". In S.D. Seth (ed.). Textbook of Pharmacology. Elsevier India. p. 31. ISBN 9788131211588. Archived from the original on 2017-09-10.
- "Impavido New FDA Drug Approval | CenterWatch". www.centerwatch.com. Archived from the original on 2016-11-04. Retrieved 2016-11-09.
- FDA. "Miltefosine (Impravido) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis" (PDF). Archived (PDF) from the original on 2016-10-24. Retrieved 9 Nov 2016.
- Cohen, Jonathan; Powderly, William G.; Opal, Steven M. (2016). Infectious Diseases. Elsevier Health Sciences. p. 1367. ISBN 9780702063381. Archived from the original on 2017-09-10.
- Teshima, K; Ikeda, K; Hamaguchi, K; Hayashi, K (1983). "Bindings of cobra venom phospholipases A2 to micelles of n-hexadecylphosphorylcholine". Journal of Biochemistry. 94 (1): 223–32. doi:10.1093/oxfordjournals.jbchem.a134333. PMID 6619110.
- Fleer, EA; Unger, C; Kim, DJ; Eibl, H (1987). "Metabolism of ether phospholipids and analogs in neoplastic cells". Lipids. 22 (11): 856–61. doi:10.1007/bf02535544. PMID 3444378.
- Berger, MR; Petru, E; Schmähl, D (1987). "Therapeutic ratio of mono or combination bacterial lipopolysaccharide therapy in methylnitrosourea-induced rat mammary carcinoma". Journal of Cancer Research and Clinical Oncology. 113 (5): 437–45. doi:10.1007/bf00390037. PMID 3624299.
- Muschiol, C; Berger, MR; Schuler, B; Scherf, HR; Garzon, FT; Zeller, WJ; Unger, C; Eibl, HJ; Schmähl, D (1987). "Alkyl phosphocholines: toxicity and anticancer properties". Lipids. 22 (11): 930–4. doi:10.1007/bf02535558. PMID 3444388.
- Berger, MR; Muschiol, C; Schmähl, D; Eibl, HJ (1987). "New cytostatics with experimentally different toxic profiles". Cancer Treatment Reviews. 14 (3–4): 307–17. doi:10.1016/0305-7372(87)90023-5. PMID 3440252.
- Eibl, H; Unger, C (1990). "Hexadecylphosphocholine: a new and selective antitumor drug". Cancer Treatment Reviews. 17 (2–3): 233–42. doi:10.1016/0305-7372(90)90053-i. hdl:11858/00-001M-0000-0013-0D40-8. PMID 2272038.
- Hilgard, P; Stekar, J; Voegeli, R; Engel, J; Schumacher, W; Eibl, H; Unger, C; Berger, MR (1988). "Characterization of the antitumor activity of hexadecylphosphocholine (D 18506)". European Journal of Cancer & Clinical Oncology. 24 (9): 1457–61. doi:10.1016/0277-5379(88)90336-7. PMID 3141197.
- Croft, S.L.; Neal, R.A.; Pendergast, W.; Chan, J.H. (1987). "The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani". Biochemical Pharmacology. 36 (16): 2633–2636. doi:10.1016/0006-2952(87)90543-0. PMID 3606662.
- Kuhlencord, A; Maniera, T; Eibl, H; Unger, C (1992). "Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice". Antimicrobial Agents and Chemotherapy. 36 (8): 1630–1634. doi:10.1128/AAC.36.8.1630. PMC 192021. PMID 1329624.
- Sundar, Shyam; Rosenkaimer, Frank; Makharia, Manoj K; Goyal, Ashish K; Mandal, Ashim K; Voss, Andreas; Hilgard, Peter; Murray, Henry W (1998). "Trial of oral miltefosine for visceral leishmaniasis". The Lancet. 352 (9143): 1821–1823. doi:10.1016/S0140-6736(98)04367-0. PMID 9851383.
- Cope, Jennifer R (2013). "Investigational drug available directly from CDC for the treatment of infections with free-living amebae". MMWR. Morbidity and Mortality Weekly Report. 62 (33): 666. PMC 4604798. PMID 23965830. Archived from the original on 2017-07-11.
- CDC (2014). "Naegleria fowleri - Primary Amebic Meningoencephalitis (PAM)". Centers for Disease Control and Prevention. Archived from the original on 14 February 2015. Retrieved 29 August 2014.
- Gholipour, Bahar (14 August 2013). "Brain-Eating Amoeba: How One Girl Survived". livescience. Archived from the original on 3 October 2014. Retrieved 29 August 2014.
- Goldschmidt, Debra; Scutti, Susan. "Rare recovery: Florida teen survives brain-eating amoeba". CNN. Archived from the original on 24 August 2016. Retrieved 23 August 2016.
- Inc., Profounda. "Profounda, Inc. launches Impavido (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States". www.prnewswire.com. Archived from the original on 2017-03-16. Retrieved 2017-05-25.
- "A life-saving drug that treats a rare infection is almost impossible to find". Archived from the original on 2016-09-19. Retrieved 2016-11-01.
- Almeida Pachioni, JD; Magalhães, JG; Cardoso Lima, EJ; Moura Bueno, LD; Barbosa, JF; Malta de Sá, M; Rangel-Yagui, CO (2013). "Alkylphospholipids - a promising class of chemotherapeutic agents with a broad pharmacological spectrum". Journal of Pharmacy & Pharmaceutical Sciences. 16 (5): 742–59. doi:10.18433/J3CW23. PMID 24393556.
- Eissa, Maha M; El Bardicy, Samia; Tadros, Menerva (2011). "Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy". Parasites & Vectors. 4 (1): 73. doi:10.1186/1756-3305-4-73. PMC 3114006. PMID 21569375.
- Saraiva V, Gibaldi D, Previato J, Mendonça-Previato L, Bozza M, Freire-De-Lima C, Heise N (2002). "Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi". Antimicrob Agents Chemother. 46 (11): 3472–7. doi:10.1128/AAC.46.11.3472-3477.2002. PMC 128733. PMID 12384352.
- Widmer F, Wright L, Obando D, Handke R, Ganendren R, Ellis D, Sorrell T (2006). "Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis". Antimicrob Agents Chemother. 50 (2): 414–21. doi:10.1128/AAC.50.2.414-421.2006. PMC 1366877. PMID 16436691.
- Blaha C, Duchêne M, Aspöck H, Walochnik J (2006). "In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis". J. Antimicrob. Chemother. 57 (2): 273–8. doi:10.1093/jac/dki417. PMID 16344287.
- Choubey V, Maity P, Guha M, et al. (2007). "Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanism". Antimicrob. Agents Chemother. 51 (2): 696–706. doi:10.1128/AAC.00919-06. PMC 1797733. PMID 17145794.
- Schuster, FL; Guglielmo, BJ; Visvesvara, GS (2006). "In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri". The Journal of Eukaryotic Microbiology. 53 (2): 121–6. doi:10.1111/j.1550-7408.2005.00082.x. PMID 16579814.
- Kim, J.-H.; Jung, S.-Y.; Lee, Y.-J.; Song, K.-J.; Kwon, D.; Kim, K.; Park, S.; Im, K.-I.; Shin, H.-J. (2008). "Effect of therapeutic chemical agents in vitro and on experimental meningoencephalitis due to Naegleria fowleri". Antimicrobial Agents and Chemotherapy. 52 (11): 4010–4016. doi:10.1128/AAC.00197-08. PMC 2573150. PMID 18765686.
- Ahmad, Arine F.; Heaselgrave, Wayne; Andrew, Peter W.; Kilvington, Simon (2013). "The in vitro efficacy of antimicrobial agents against the pathogenic free-living amoeba Balamuthia mandrillaris". Journal of Eukaryotic Microbiology. 60 (5): 539–543. doi:10.1111/jeu.12062. PMID 23869955.
- Rijal, S.; Ostyn, B.; Uranw, S.; Rai, K.; Bhattarai, N. R.; Dorlo, T. P. C.; Beijnen, J. H.; Vanaerschot, M.; Decuypere, S.; Dhakal, S. S.; Das, M. L.; Karki, P.; Singh, R.; Boelaert, M.; Dujardin, J.-C. (2013). "Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance". Clinical Infectious Diseases. 56 (11): 1530–1538. doi:10.1093/cid/cit102. PMID 23425958.
- Rai, K.; Cuypers, B.; Bhattarai, N. R.; Uranw, S.; Berg, M.; Ostyn, B.; Dujardin, J.-C.; Rijal, S.; Vanaerschot, M. (2013). "Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain". mBio. 4 (5): e00611–13–e00611–13. doi:10.1128/mBio.00611-13. PMC 3791894. PMID 24105765.
- Dorlo, T. P. C.; Rijal, S.; Ostyn, B.; de Vries, P. J.; Singh, R.; Bhattarai, N.; Uranw, S.; Dujardin, J.-C.; Boelaert, M.; Beijnen, J. H.; Huitema, A. D. R. (2014). "Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure". Journal of Infectious Diseases. 210 (1): 146–153. doi:10.1093/infdis/jiu039. PMID 24443541.
- Ostyn, Bart; Hasker, Epco; Dorlo, Thomas P. C.; Rijal, Suman; Sundar, Shyam; Dujardin, Jean-Claude; Boelaert, Marleen; Ng, Lisa FP. (2014). "Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia". PLoS ONE. 9 (6): e100220. Bibcode:2014PLoSO...9j0220O. doi:10.1371/journal.pone.0100220. PMC 4062493. PMID 24941345.
- Vila, Taissa V. M.; Ishida, Kelly; Souza, Wanderley de; Prousis, Kyriakos; Calogeropoulou, Theodora; Rozental, Sonia (2013-01-01). "Effect of alkylphospholipids on Candida albicans biofilm formation and maturation". Journal of Antimicrobial Chemotherapy. 68 (1): 113–125. doi:10.1093/jac/dks353. ISSN 0305-7453. PMID 22995097.
- Chugh P, Bradel-Tretheway B, Monteiro-Filho CM, et al. (2008). "Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy". Retrovirology. 5 (1): 11. doi:10.1186/1742-4690-5-11. PMC 2265748. PMID 18237430.
- "Parasitic Drug Shows HIV-Fighting Promise". AIDSmeds.com. 2008-02-01. Archived from the original on 2008-02-12. Retrieved 2008-02-02.
- Garg, Ravendra; Tremblay, Michel J. (2012). "Miltefosine represses HIV-1 replication in human dendritic cell/T-cell cocultures partially by inducing secretion of type-I interferon". Virology. 432 (2): 271–276. doi:10.1016/j.virol.2012.05.032. PMID 22704066.